UniDoc Health Corp. Provides Corporate Update
UniDoc Health Corp. (OTCQB:UDOCF) has provided a comprehensive corporate update addressing several key developments. The company has completed filing its delayed annual financial statements for the year ended March 31, 2025, which had resulted in a Cease Trade Order (CTO) from the British Columbia Securities Commission. The delay was attributed to extended audit timelines and a required independent valuation of the AGNES Connect Software acquisition from AMD Global Telemedicine.
The company reports successful integration of AGNES software into its operations, with positive client response and contract renewals. UniDoc has also begun shipping its H3 Health Cube units and expects to announce customer installations soon. The company operates in the global telemedicine market, which is projected to grow from $146.9 billion in 2025 to $251.5 billion by 2030, representing an 11.3% CAGR.
UniDoc Health Corp. (OTCQB:UDOCF) ha pubblicato un aggiornamento aziendale completo su diversi sviluppi chiave. La società ha completato il deposito delle sue dichiarazioni finanziarie annuali ritardate per l'esercizio conclusosi il 31 marzo 2025, il cui ritardo aveva comportato un Ordine di Cessazione delle Negoziazioni (CTO) dalla British Columbia Securities Commission. Il ritardo è stato attribuito a tempi di revisione più lunghi del previsto e alla necessità di una valutazione indipendente dell'acquisizione del software AGNES Connect da AMD Global Telemedicine.
La società riferisce di aver integrato con successo il software AGNES nelle sue operazioni, con riscontri positivi da parte dei clienti e rinnovi contrattuali. UniDoc ha inoltre iniziato la spedizione delle sue unità H3 Health Cube e prevede di annunciare a breve le installazioni presso i clienti. L'azienda opera nel mercato globale della telemedicina, che si prevede crescerà da 146,9 miliardi di dollari nel 2025 a 251,5 miliardi di dollari nel 2030, con un CAGR dell'11,3%.
UniDoc Health Corp. (OTCQB:UDOCF) ha proporcionado una actualización corporativa detallada sobre varios desarrollos clave. La compañía completó la presentación de sus estados financieros anuales retrasados correspondientes al ejercicio finalizado el 31 de marzo de 2025, cuyo retraso había dado lugar a una Orden de Cese de Negociación (CTO) por parte de la British Columbia Securities Commission. El retraso se atribuyó a plazos de auditoría prolongados y a la necesidad de una valoración independiente de la adquisición del software AGNES Connect a AMD Global Telemedicine.
La empresa informa que ha integrado con éxito el software AGNES en sus operaciones, con respuesta positiva de sus clientes y renovaciones de contratos. UniDoc también ha comenzado a enviar sus unidades H3 Health Cube y espera anunciar pronto las instalaciones de clientes. La compañía opera en el mercado global de telemedicina, que se proyecta crecerá de 146,9 mil millones de dólares en 2025 a 251,5 mil millones de dólares para 2030, con un CAGR del 11,3%.
UniDoc Health Corp. (OTCQB:UDOCF)는 여러 주요 진행 사항에 대한 포괄적인 회사 업데이트를 발표했습니다. 회사는 2025년 3월 31일로 종료되는 연도에 대한 지연된 연간 재무제표 제출을 완료했으며, 이 지연으로 인해 브리티시컬럼비아 증권위원회로부터 거래중단명령(CTO)이 발령된 바 있습니다. 지연 사유는 감사 일정의 연장과 AMD Global Telemedicine로부터 인수한 AGNES Connect 소프트웨어의 독립 평가 필요성 때문이었습니다.
회사는 AGNES 소프트웨어를 운영에 성공적으로 통합했으며, 고객 반응과 계약 갱신이 긍정적이라고 보고했습니다. UniDoc은 또한 H3 Health Cube 유닛의 출하를 시작했으며 곧 고객 설치 소식을 발표할 것으로 예상합니다. 회사는 글로벌 원격의료 시장에서 활동하고 있으며, 이 시장은 2025년 1,469억 달러에서 2030년 2,515억 달러로 성장하여 연평균복합성장률(CAGR) 11.3%를 기록할 전망입니다.
UniDoc Health Corp. (OTCQB:UDOCF) a publié une mise à jour complète sur plusieurs évolutions clés. La société a finalisé le dépôt de ses états financiers annuels retardés pour l'exercice clos le 31 mars 2025, dont le retard avait entraîné une ordonnance de cessation des négociations (Cease Trade Order, CTO) émise par la British Columbia Securities Commission. Ce retard a été attribué à des délais d'audit prolongés et à la nécessité d'une évaluation indépendante de l'acquisition du logiciel AGNES Connect auprès d'AMD Global Telemedicine.
La société indique avoir intégré avec succès le logiciel AGNES à ses opérations, avec des retours positifs des clients et des renouvellements de contrats. UniDoc a également commencé l'expédition de ses unités H3 Health Cube et s'attend à annoncer prochainement des installations chez ses clients. L'entreprise opère sur le marché mondial de la télémédecine, qui devrait passer de 146,9 milliards de dollars en 2025 à 251,5 milliards de dollars en 2030, soit un taux de croissance annuel composé (CAGR) de 11,3 %.
UniDoc Health Corp. (OTCQB:UDOCF) hat ein umfassendes Unternehmensupdate zu mehreren wichtigen Entwicklungen veröffentlicht. Das Unternehmen hat die verspätet eingereichten Jahresabschlüsse für das am 31. März 2025 endende Geschäftsjahr fertiggestellt, deren Verzögerung zu einer Handelssperre (Cease Trade Order, CTO) durch die British Columbia Securities Commission geführt hatte. Die Verzögerung wurde auf verlängerte Abschlussprüfungszeiträume und auf eine erforderliche unabhängige Bewertung der AGNES Connect Software-Akquisition von AMD Global Telemedicine zurückgeführt.
Das Unternehmen meldet die erfolgreiche Integration der AGNES-Software in seine Abläufe, mit positivem Kundenfeedback und Vertragsverlängerungen. UniDoc hat außerdem mit dem Versand seiner H3 Health Cube-Einheiten begonnen und erwartet, bald Kundeninstallationen bekannt zu geben. Das Unternehmen ist im globalen Telemedizinmarkt tätig, der voraussichtlich von 146,9 Milliarden USD im Jahr 2025 auf 251,5 Milliarden USD im Jahr 2030 wachsen wird, was einem CAGR von 11,3 % entspricht.
- None.
- Delayed filing of annual financial statements resulted in a Cease Trade Order
- Extended audit timelines and valuation requirements affected regulatory compliance
- Trading remains suspended pending CTO revocation
VANCOUVER, BC / ACCESS Newswire / August 28, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or "the Company") pleased to provide shareholders with a general corporate update, including an update on its financial filings, corporate activities, and market positioning.
Financial statement filing update
UniDoc announces that the filing of its annual financial statements, accompanying management discussion and analysis, and certifications for the financial year ended March 31, 2025, previously expected to be filed by July 31, 2025, is now completed. The delay was primarily due to extended timelines in completing the Company's annual audit, including a one-time requirement for an independent valuation of the purchased AGNES Connect Software from AMD Global Telemedicine, which resulted in a Cease Trade Order ("CTO") issued by the British Columbia Securities Commission on August 5, 2025.
The Company remains fully committed to strengthening its internal procedures to ensure timely and accurate filings in the future. We sincerely appreciate our shareholders' continued support and patience during this time of growth.
UniDoc is well-positioned for strong forward momentum, with the revocation of the CTO and resumption of trading expected shortly after the filing of its financial statements. We look ahead to an active and productive corporate calendar, with several key initiatives and milestones set to drive meaningful progress in the months ahead.
Corporate update
AMD software integration: The AGNES Connect® software ("AGNES") and related assets acquired from AMD Telemedicine have now been fully integrated into UniDoc's operations. To date the Company has observed a positive client response, including renewals of contracts that were coming due. Additionally, the Company has partnered with sales consultants that specialize in AGNES software, including former AMD CEO Eric Bacon, which has expanded its sales reach.
Order fulfillment: UniDoc continues to make progress with deployment of the UniDoc H3 Health Cube. Recently several cubes have been shipped from the factory, and the Company expects to announce the installations with customers in the coming weeks.
Telemedicine Sector
The global telemedicine market is entering a sustained growth phase, projected to expand from
On Behalf of the Board of Directors,
~Antonio (Tony) Baldassarre~
Antonio Baldassarre
CEO, President & Director
UniDoc Health Corp.
About UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF)
UniDoc is developing an eHealth solution which is being designed as a self-contained remote virtual clinic within a private kiosk for patients to undergo full consultations as if they were present in a physician's office. eHealth opens the doors to a large segment of the population challenged by access, experience or understanding of online computer technology. It is the Company's belief that physical accessibility is the key to its business proposition. UniDoc is dedicated to unlocking shareholder value by delivering an excellent product and sophisticated commercial network within an expedited timeframe. The UniDoc team encourages engagement, questions, and interest, so please stay in touch and invite anyone who might be interested in our story to visit our website at www.unidoctor.com and signup to receive the latest information with updates on our activities, events and progress.
For further information, please contact:
UniDoc Investor Relations
Tel: +1 778.383.6731
Email: info@unidoctor.com
Matt Chatterton, Director
Tel: +1 778.613.2082
Email: matt@unidoctor.com
Media Inquiries media@unidoctor.com
Forward-Looking Statements
This news release contains statements and information that, to the extent that they are not historical fact, may constitute "forward-looking information" within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as "may", "would", "could", "will", "will be", "likely", "expect", "anticipate", "believe", "intend", "plan", "forecast", "project", "estimate", "outlook", or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the revocation of the CTO and resumption of trading, an active and productive corporate calendar for the Company; the installations with customers of the UniDoc H3 Health Cube and announcements thereof.
Forward-looking information is based on the assumptions, estimates, analysis, and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; the Company's ability to secure additional financing on reasonable terms; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all; as well as all of the other risks as described in the Company's annual management discussion and analysis dated July 31, 2024 under the heading "Risks Factors." Accordingly, readers should not place undue reliance on any such forward-looking information.
Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company's management to predict all such factors and to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE: UniDoc Health Corp.
View the original press release on ACCESS Newswire
FAQ
Why was UniDoc Health Corp (UDOCF) issued a Cease Trade Order in August 2025?
What progress has UniDoc Health made with the AGNES Connect software integration?
What is the current status of UniDoc's H3 Health Cube deployment?
What is the projected growth for the global telemedicine market according to UniDoc's update?
When does UniDoc expect trading to resume after the Cease Trade Order?
